Stay updated on APL-2 in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the APL-2 in Neovascular AMD Clinical Trial page.

Latest updates to the APL-2 in Neovascular AMD Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study page’s error changes from a 403 Forbidden response to “TypeError: Failed to fetch,” and the NIH transition notice is no longer shown.SummaryDifference1%

- Check20 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces NIH website updates and says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence,” with both terms appearing during the transition.SummaryDifference1%

- Check34 days agoChange DetectedThe site footer revision identifier changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0 on the 403 error page.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now shows a 403 Forbidden error, indicating the study record is temporarily inaccessible. The standard page chrome (header/footer) remains visible while the main content is unavailable.SummaryDifference17%

Stay in the know with updates to APL-2 in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 in Neovascular AMD Clinical Trial page.